12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALKS 37: Preliminary Phase II data

Preliminary data from a double-blind, U.S. Phase II trial in 87 patients diagnosed with OBD during treatment with opioids for chronic, non-cancer pain showed that once-daily 30 and 100 mg oral ALKS 37 met the primary endpoint of significantly increasing the average number of SBMs per week from baseline to week 2 vs. placebo....

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >